Business
Philip Morris International Urges FDA Advisory Committee to Recommend Authorizing ZYN as a Modified Risk Tobacco Product
STAMFORD, CT, January 23, 2026--Experts from Philip Morris International (PMI) (NYSE: PM) yesterday presented scientific evidence to the U.S. Food and Drug Administration’s (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) as part of the FDA’s process for a Modified Risk Tobacco Product (MRTP) designation for their ZYN nicotine pouch products. This designation would allow PMI’s U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that switching comp
About this update from Philip Morris International Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3543,"height":612,"url":"https://media.zenfs.com/en/business-wire.com/40ccd18f963eba0e06a73017bfbdce7c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Blzh61m1TLWECJRwPuPiZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/40ccd18f963eba0e06a73017bfbdce7c","width":960,"height":166},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/B51oNXt6vqFIEo.XxtzF0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/40ccd18f963eba0e06a73017bfbdce7c","width":1200,"height":207}},"lazy":false},{"type":"text","content":"In January 2025, ZYN became the first nicotine pouch product authorized for marketing by the FDA","length":96,"tagName":"p","attribs":{}},{"type":"text","content":"STAMFORD, CT, January 23, 2026--(BUSINESS WIRE)--Experts from Philip Morris International (PMI) (NYSE: PM) yesterday presented scientific evidence to the U.S. Food and Drug Administration’s (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) as part of the FDA’s process for a Modified Risk Tobacco Product (MRTP) designation for their ZYN nicotine pouch products. This designation would allow PMI’s U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that switching completely to ZYN reduces their risk of many smoking-related diseases and we look forward to a decision by FDA.","length":624,"tagName":"p"},{"type":"text","content":""The FDA’s Center for Tobacco Product’s (CTP) mission is to make smoking-related disease and death a part of America’s past," said Keagan Lenihan, Chief External Affairs Officer for PMI U.S. "Smoke-free products, like ZYN, play a critical role in helping CTP achieve this mission and provide adults who smoke with important information to guide their choices and a real opportunity to change.","length":407,"tagName":"p"},{"type":"text","content":"The full-day meeting on January 22 was part of the FDA’s scientific review of PMI-affiliate Swedish Match USA Inc.’s application to use the following proposed reduced risk claim: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic b...